X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TEVA PHARMA (Israel) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
TEVA PHARMA
Dec-13
GLENMARK PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs9303,026-   
Low Rs5172,629-   
Sales per share (Unadj.) Rs322.61,736.8-  
Earnings per share (Unadj.) Rs28.5108.5-  
Cash flow per share (Unadj.) Rs39.2248.9-  
Dividends per share (Unadj.) Rs2.0094.98-  
Dividend yield (eoy) %0.33.4 8.2%  
Book value per share (Unadj.) Rs183.01,929.2-  
Shares outstanding (eoy) m282.17848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.6 137.8%   
Avg P/E ratio x25.426.1 97.5%  
P/CF ratio (eoy) x18.511.4 162.6%  
Price / Book Value ratio x4.01.5 269.8%  
Dividend payout %7.087.5 8.0%   
Avg Mkt Cap Rs m204,2062,397,720 8.5%   
No. of employees `00013.744.9 30.5%   
Total wages/salary Rs m18,7180-   
Avg. sales/employee Rs Th6,636.832,768.2 20.3%   
Avg. wages/employee Rs Th1,364.70-   
Avg. net profit/employee Rs Th586.12,047.0 28.6%   
INCOME DATA
Net Sales Rs m91,0311,472,765 6.2%  
Other income Rs m9140-   
Total revenues Rs m91,9451,472,765 6.2%   
Gross profit Rs m16,154403,318 4.0%  
Depreciation Rs m3,019119,045 2.5%   
Interest Rs m2,85628,928 9.9%   
Profit before tax Rs m11,193255,345 4.4%   
Minority Interest Rs m01,160 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-167,620 0.0%   
Tax Rs m3,155-3,118 -101.2%   
Profit after tax Rs m8,03992,003 8.7%  
Gross profit margin %17.727.4 64.8%  
Effective tax rate %28.2-1.2 -2,308.4%   
Net profit margin %8.86.2 141.4%  
BALANCE SHEET DATA
Current assets Rs m69,887994,700 7.0%   
Current liabilities Rs m32,879867,463 3.8%   
Net working cap to sales %40.78.6 470.6%  
Current ratio x2.11.1 185.4%  
Inventory Days Days8191 89.7%  
Debtors Days Days9396 97.5%  
Net fixed assets Rs m28,892481,038 6.0%   
Share capital Rs m2823,625 7.8%   
"Free" reserves Rs m51,3530-   
Net worth Rs m51,6351,635,963 3.2%   
Long term debt Rs m41,418753,058 5.5%   
Total assets Rs m125,9543,365,740 3.7%  
Interest coverage x4.99.8 50.1%   
Debt to equity ratio x0.80.5 174.3%  
Sales to assets ratio x0.70.4 165.2%   
Return on assets %8.63.6 240.7%  
Return on equity %15.65.6 276.8%  
Return on capital %15.14.9 306.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m26,5980-   
CASH FLOW
From Operations Rs m16,481234,683 7.0%  
From Investments Rs m-10,133-83,158 12.2%  
From Financial Activity Rs m-4,685-281,518 1.7%  
Net Cashflow Rs m1,770-129,993 -1.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.5 Rs / USD

Compare GLENMARK PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare GLENMARK PHARMA With: TORRENT PHARMA  PANACEA BIOTECH  JUBILANT LIFE SCIENCES  SHASUN PHARMA  WOCKHARDT LTD.  



Today's Market

Sensex Opens Flat; Capital Goods & Banking Stocks Lag(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.5% while the Hang Seng is down 1.2%.

Related Views On News

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 13, 2018 09:47 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS